Non-small-cell lung cancer (NSCLC) has become a paradigm of precision medicine, with
the discovery of numerous disease subtypes defined by specific oncogenic driver mutations …

BRAF mutations are reported in about 3–5% of non-small-cell lung cancer (NSCLC), almost
exclusively in adenocarcinoma histology, and are classified into three different classes. The …

Currently, lung cancer is treated by the highest number of therapeutic options and the
benefits are based on multiple large‐scale sequencing studies, translational research and …

In recent years, various types of immunotherapy, particularly the use of immune checkpoint
inhibitors targeting programmed cell death 1 or programmed death ligand 1 (PD-L1), have …

Purpose: Even though BRAF fusions are increasingly detected in standard multigene next-
generation sequencing panels, few reports have explored their structure and impact on …

BRAF and cMET exon 14 skip** are rare mutations of NSCLC. The treatment sequence in
these cases for the first and second line is not clear. An international registry was created for …

Background Despite immune checkpoint inhibitors (ICI) being widely used to treat patients
with advanced non-small cell lung cancer (NSCLC), few studies examine the role of ICI in …

Abstract Introduction BRAF non-V600E mutations occur in 1% to 2% of NSCLCs. Because of
their rarity, the clinical backgrounds and outcomes of cytotoxic chemotherapy or …

Simple Summary Non-small cell lung cancer (NSCLC) patients harboring BRAF non-V600
alterations constitute a heterogeneous and poorly studied population orphan of targeted …

Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer, accounting
for approximately 85% of cases of lung cancer. The standard first-line therapy for patients …